Puretech founded entity vedanta biosciences announces new data from phase 1 study of ve202 for the treatment of inflammatory bowel disease

Boston--(business wire)--puretech health plc (nasdaq: prtc, lse: prtc) (“puretech” or the “company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its founded entity, vedanta biosciences, announced additional results from a phase 1 study in healthy volunteers of ve202, vedanta's 16-strain live biotherapeutic product (lbp) candidate for inflammatory bowel disease
PRTC Ratings Summary
PRTC Quant Ranking